Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
HIV & AIDS
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
Related Questions
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
Do you favor a certain NRTI to pair with dolutegravir and lamivudine in persons with HIV to minimize the risk of resistance to dolutegravir?
Do you recommend to continue acyclovir to prevent HSV infection in an HIV patient with CD4 count more than 200 and with high viral load?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
Would you recommend switching from an integrase strand transfer inhibitor-based regimen to a different antiretroviral regimen, or would you instead add weight loss medications for a person with HIV experiencing weight gain that has not improved with lifestyle changes?
What are your top takeaways from ID Week 2024?
Do you have any concerns about using long-acting cabotegravir/rilpivirine in obese patients with HIV?
How do you use CD4% in clinical practice in management of patients living with HIV?
How do you approach the use of Paxlovid in patients with COVID-19 and CKD Stage 4?
